Interní Med. 2011; 13(9): 337-339

What new drugs to expect in treating dyslipidaemia?

MUDr.Michal Vrablík, Ph.D.

Centrum preventivní kardiologie, 3. interní klinika 1. LF UK a VFN v Praze

At present, hypolipidaemic treatment is an essential strategy to reduce the risk of a cardiovascular event. By combining treatments, this

risk can be reduced beyond the possibilities of monotherapy in some cases. Still, a number of patients fail to achieve a desirable reduction

in atherogenic serum lipids even despite using all available treatment options. Intensive research is currently under way and a number

of new drugs affecting the levels of LDL-cholesterol (mipomersen, eprotirome, PCSK-9 inhibitors), HDL-cholesterol (CETP inhibitors,

apoA1 analogue) or triglycerides (all the above-mentioned drugs and MTP inhibitors) are in the phase of clinical trials. If the theoretical

assumptions are correct and if the new molecules pass demanding clinical testing successfully, we as well as our patients will live to see

new possibilities of reducing the risk of atherothrombotic vascular complications.

Keywords: dyslipidaemia, hypolipidaemic drugs, mipomersen, eprotirome, trapibs, cardiovascular risk

Published: September 1, 2011  Show citation